Therapies targeting enzymes that initiate collagen cross-linking (e.g., anti-LOX or -lysyl oxidase-like 2 antibodies) decrease tumor stiffness and suppress metastasis in mouse models of cancer1, 6, 39, 40. The gene discussed is LOXL2; the disease is neoplasm.